ArticlemAbs2018
Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD
Registry-linked trialOpen access · goldAbstract read
In one paragraph
Article in mAbs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01704716 (High Risk Neuroblastoma Study 1 of SIOP-Europe), which is not on this map. Cited by 48 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Efficacy and Safety of Anti-GD2 Immunotherapy with Dinutuximab Beta in the Treatment of Relapsed/Refractory High-Risk Neuroblastoma.Targeted oncology · 2025Pooled it
- Commonly Reported Adverse Events Associated With Pediatric Immunotherapy: A Systematic Review From the Children's Oncology GroupJournal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology NursesPooled it
- Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study.British journal of cancer · 2023Trial
- Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.Frontiers in immunology · 2021Trial
- mRNA vaccination using peptide nanoparticles triggers a strong immune response against endogenous GPC2 in a murine neuroblastoma model.Molecular therapy. Oncology · 2026Article
- Efficacy and safety of dinutuximab beta combined with GM-CSF and isotretinoin ± chemotherapy as first-line maintenance treatment for pediatric high-risk neuroblastoma in China.Frontiers in oncology · 2026Article
- Systematic Targeting of GD2-Positive Neuroblastoma Tumors With a Photooncolytic Phage Nanovector Platform.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Article
- Strategies to manage the adverse effects of immunotherapy with dinutuximab beta in neuroblastoma: an Italian experience and literature review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Review
- Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons.Frontiers in oncology · 2025Article
- GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma.International journal of cancer · 2024Review
- Toxicity Spectrum of Anti-GD2 Immunotherapy: A Real-World Study Leveraging the US Food and Drug Administration Adverse Event Reporting System.Paediatric drugs · 2024Article
- Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3.Cancer immunology, immunotherapy : CII · 2024Article
- GD2-targeting therapy: a comparative analysis of approaches and promising directions.Frontiers in immunology · 2024Review
- Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects.Frontiers in oncology · 2024Article
- Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings-Real-World Data.Journal of clinical medicine · 2023Article
- IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models.Journal for immunotherapy of cancer · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 5 countries.
Ina Muellera Department of Pediatric Oncology , University Medicine Greifswald , Greifswald , Germany.
Karoline Ehlerta Department of Pediatric Oncology , University Medicine Greifswald , Greifswald , Germany.
Stefanie Endresa Department of Pediatric Oncology , University Medicine Greifswald , Greifswald , Germany.
Lena Pilla Department of Pediatric Oncology , University Medicine Greifswald , Greifswald , Germany.
Nikolai Sieberta Department of Pediatric Oncology , University Medicine Greifswald , Greifswald , Germany.
Silke Kietza Department of Pediatric Oncology , University Medicine Greifswald , Greifswald , Germany.
Penelope Brockb Great Ormond Street Hospital, Department of Pediatric Hematology and Oncology , London , United Kingdom.
Alberto Garaventac Department of Pediatric Hematology and Oncology , Gaslini Institute , Genova Italy.
Dominique Valteau-Couanetd Department of Pediatric and Adolescent Oncology Villejuif , Gustave Roussy Université Paris-Sud , France.
Evelyne Janzeke Apeiron Biologics , Vienna , Austria.
Norbert Hostenf Department of Radiology and Nuclear Medicine , University Medicine Greifswald , Greifswald , Germany.
Andreas Zinkef Department of Radiology and Nuclear Medicine , University Medicine Greifswald , Greifswald , Germany.
Winfried Barthleng Department of Pediatric Surgery , University Medicine Greifswald , Greifswald , Germany.
Emine Varolg Department of Pediatric Surgery , University Medicine Greifswald , Greifswald , Germany.
Hans Loibnere Apeiron Biologics , Vienna , Austria.
Ruth Ladensteinh St. Anna Children's Hospital , Department of Pediatric Hematology and Oncolgoy , Vienna , Austria.
Holger N Lodea Department of Pediatric Oncology , University Medicine Greifswald , Greifswald , Germany.ORCID 0000-0002-1201-208X
Universitätsmedizin Greifswald · DEApeiron Biologics (Austria) · ATGreat Ormond Street Hospital · GBIstituto Giannina Gaslini · ITSt Anna Children's Hospital · ATUniversité Paris-Sud · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy with short term infusion (STI) of monoclonal anti-GD
Indexed as
AdolescentAdultAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsChildChild, PreschoolDrug Administration ScheduleFemaleGangliosidesHumansImmunotherapyInfantInfusions, IntravenousInterleukin-2IsotretinoinAntibodies, MonoclonalAntineoplastic Agents, Immunologicaldinutuximabganglioside, GD2GangliosidesInterleukin-2Isotretinoinanti-GD2 antibodych14.18/CHOimmunotherapyneuroblastoma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT01704716ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.